Literature DB >> 11560205

Fenofibrate-Induced elevation in serum creatinine.

J L Ritter1, S Nabulsi.   

Abstract

Fenofibrate, a fibric acid derivative, is used as adjunctive therapy with diet for treatment of hyperlipidemia. Side effects include gastrointestinal complaints and, rarely, elevations in liver function tests. According to the drug's package insert, elevations in serum creatinine may occur; although, no postmarketing case reports of fenofibrate-induced elevations in serum creatinine are on file with the manufacturer. Fenofibrate was the probable cause of elevations in serum creatinine concentrations in six patients at our clinic. As the implications of these elevations may be serious, routine serum creatinine monitoring is recommended at baseline and 1-2 months after starting fenofibrate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11560205     DOI: 10.1592/phco.21.13.1145.34623

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  7 in total

Review 1.  An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature.

Authors:  Christine B Bruno; Jeffrey M Schapiro; Parya Saberi
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2011-04-25

Review 2.  Fibrate therapy and renal function.

Authors:  Domenic A Sica
Journal:  Curr Atheroscler Rep       Date:  2009-09       Impact factor: 5.113

3.  New metabolites of fenofibrate in Sprague-Dawley rats by UPLC-ESI-QTOF-MS-based metabolomics coupled with LC-MS/MS.

Authors:  A Liu; Y Chen; Z Yang; Y Feng; W Rui; W Luo; Y Liu; F J Gonzalez; R Dai
Journal:  Xenobiotica       Date:  2009-04       Impact factor: 1.908

Review 4.  Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.

Authors:  Gillian M Keating; Douglas Ormrod
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics.

Authors:  Aiming Liu; Andrew D Patterson; Zongtao Yang; Xinying Zhang; Wei Liu; Fayang Qiu; He Sun; Kristopher W Krausz; Jeffrey R Idle; Frank J Gonzalez; Renke Dai
Journal:  Drug Metab Dispos       Date:  2009-02-27       Impact factor: 3.922

6.  Effect of Fenofibrate Medication on Renal Function.

Authors:  Sungjong Kim; Kyungjin Ko; Sookyoung Park; Dong Ryul Lee; Jungun Lee
Journal:  Korean J Fam Med       Date:  2017-07-20

7.  Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.

Authors:  Koutaro Yokote; Shizuya Yamashita; Hidenori Arai; Eiichi Araki; Hideki Suganami; Shun Ishibashi; On Behalf Of The K-Study Group
Journal:  Int J Mol Sci       Date:  2019-02-06       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.